These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Cancer immunotherapy targeting the telomerase reverse transcriptase.
    Author: Huo LF, Tang JW, Huang JJ, Huang PT, Huang CF, Kung HF, Lin MC.
    Journal: Cell Mol Immunol; 2006 Feb; 3(1):1-11. PubMed ID: 16549043.
    Abstract:
    The human telomerase reverse transcriptase (hTERT) is expressed in more than 85% of tumor cells but is usually not found in normal cells, which makes hTERT as an ideal tumor-associate antigen (TAA) to develop potential vaccine specifically destroying cancers without impairing normal tissues in human cancer immunotherapy. Here are reviewed the fundamental advances of studies on immunogenicity of hTERT or its peptides and the early clinical trials using the hTERT vaccine approach in the last decades.
    [Abstract] [Full Text] [Related] [New Search]